Genzyme, of Cambridge, Mass., a Sanofi company, said the Australian Therapeutic Goods Administration approved Lemtrada (alemtuzumab) for the treatment of relapsing forms of multiple sclerosis (MS) for patients with active disease defined by clinical or imaging features to slow the accumulation of physical disability and reduce the frequency of clinical relapses.